Have you got any qualifications? http://xnxx.in.net/xxnx/ Xxnx This is the second drug developed by Genmab to receive breakthrough therapy designation, the other being daratumumab (partnered with Johnson & Johnson) for multiple myeloma. The FDA approved Arzerra for CLL in October 2009 for patients who have not responded to Sanofi unit Genzyme’s Campath (alemtuzumab) or fludarabine.